TB-500

The recovery peptide people pair with BPC-157. Here’s what the research actually covers, what users report and why TB-500 is not the same as full-length thymosin beta-4.

What is it?A synthetic 7-amino-acid fragment (Ac-LKKTETQ) of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein involved in cell movement and tissue repair. TB-500 was first chemically identified in 2012, in samples seized as part of horse-racing doping investigations.¹

Why are people interested?Injury recovery, tendon and muscle healing, and general tissue repair — usually alongside BPC-157, with which it's commonly "stacked."¹²

Human researchNo completed human trial of the TB-500 fragment itself has been published. A purported trial listing circulating online describes itself as a fictional example and should not be treated as evidence of an active clinical study. Most existing human trial data belongs to full-length Tβ4 — a related but distinct, longer molecule — not to TB-500.^317181920

Animal & lab researchExtensive for full-length Tβ4 (wound healing, cardiac repair, muscular dystrophy models since the late 1990s); thinner and more recent for the TB-500 fragment specifically, including a 2026 head-to-head rat tendon study.^1213141516

Development & regulatory statusInvestigational, not FDA-approved. Recently removed from an FDA "do not compound" list; an FDA advisory committee has recommended — over its own staff's objection — adding it to the list of substances licensed pharmacies can legally compound. Banned at all times in Olympic and other WADA-governed sport.⁴⁵⁶¹⁰

Why People Explore TB-500

Tendons, ligaments, muscle recovery and wound healing are the main reasons people investigate TB-500. The crucial distinction: human trials of full-length thymosin beta-4 do not establish that the short TB-500 fragment works the same way.

Wound Healing & Tissue Repair

Evidence: Indirect: full-length Tβ4 human research

What the Research Says

This is the foundational claim behind TB-500, but almost all of the supporting human evidence belongs to full-length thymosin beta-4 (Tβ4, 43 amino acids), not the 7-amino-acid TB-500 fragment sold online. RegeneRx Biopharmaceuticals completed a peer-reviewed Phase 2, randomized, placebo-controlled trial of topical Tβ4 gel in patients with venous stasis ulcers, testing three concentrations against placebo.¹⁷ A companion Phase 2 dry-eye trial found mixed results — its co-primary endpoints didn't reach significance, though a secondary measure showed improvement — and a separate Phase 2 corneal-wound trial was terminated early for slow enrollment.¹⁸¹⁹ The foundational animal finding is a 1999 rat full-thickness wound study, in which topical and injected Tβ4 measurably sped healing and increased collagen deposition.¹⁶ None of this human trial history involved the TB-500 fragment itself.

What the Real World Says

Wound and tissue-repair claims are the entry point for almost everyone who looks into TB-500, and it's near-universally discussed alongside BPC-157 as a recovery "stack," sometimes called the "Wolverine Stack" in commercial and community sources — a name that shows up consistently enough across independent sources to note, though it originates largely in seller marketing rather than organic community coinage.¹² Beyond that framing, we found little independent, structured discussion of wound-healing experiences specifically, as opposed to the broader injury-recovery framing covered in the next topic.

See the ResearchStudies, numbers and limits

The core distinction

TB-500 is a synthetic copy of just the actin-binding region of Tβ4 (residues 17-23). It's chemically related to the full molecule and shares some of its proposed mechanism, but it is not the same compound, and results from one don't automatically transfer to the other — the same caution that applies when a peptide has a modified analog with its own separate trial history (as with other peptides on this site).¹¹⁶

What the human Tβ4 trials found

Venous stasis ulcers (Phase 2, completed): three gel concentrations (0.01%, 0.03%, 0.1% w/w) tested against placebo in patients with ulcers present for at least 6 weeks.¹⁷
Dry eye (Phase 2, completed): 72 subjects, 0.1% Tβ4 eye drops vs. placebo for 28 days; co-primary endpoints of discomfort and corneal staining did not reach statistical significance, though a secondary discomfort measure improved by 27%.¹⁸
Corneal wounds in diabetic patients after vitrectomy (Phase 2, terminated): stopped for slow recruitment, not for a safety finding.¹⁹

Limitations

No completed, published human trial has tested the TB-500 fragment itself for any wound-healing indication.³
The completed Tβ4 trials are all industry-sponsored (RegeneRx Biopharmaceuticals / ReGenTree).¹⁷¹⁸¹⁹
Full-length Tβ4 still holds only orphan-drug designation for one indication, with no full FDA marketing approval as of this build.

Tendon, Muscle & Injury Recovery

Evidence: Mostly Animal & Lab Research

What the Research Says

This is the most commonly marketed use for TB-500 specifically — and, honestly, it's the thinnest part of the evidence base. A 2026 peer-reviewed rat study directly compared BPC-157 and TB-500 (alone and combined) on Achilles tendon healing after surgical transection, using biomechanical and histological measures over four weeks.¹² The study's own authors noted the reason they ran it: "in contrast to BPC-157, experimental evidence supporting the role of TB-500 in tendon-specific healing remains scarce, and controlled studies in Achilles tendon injury models are largely absent from the literature."¹² That is: even the animal evidence for TB-500's single most-marketed use is described by the researchers who study it as scarce.

What the Real World Says

Injury recovery — tendons, muscle strains, general "nagging" injuries — is what almost all real-world interest in TB-500 centers on, typically framed as working "systemically" (throughout the body) in contrast to BPC-157's more locally-framed reputation. We found this framing repeated consistently across commercial/clinic sources, but did not find independent, structured community reporting substantial enough to say how outcomes actually compare to the claims.

See the ResearchStudies, numbers and limits

In the 2026 Achilles tendon rat study, TB-500 was dosed at 60 µg/kg/day intraperitoneally for four weeks (versus BPC-157 at 10 µg/kg/day); the paper is described here for study-design context, not as usable human guidance — no validated human dose exists for TB-500.¹²

The dystrophin-deficient (mdx) mouse model of Duchenne muscular dystrophy is the other major muscle-related animal finding for full-length Tβ4: chronic treatment increased the number of regenerating skeletal-muscle fibers, though it did not significantly improve measured grip strength or cardiac function in that model.¹⁵

Cardiac Repair

Evidence: Indirect: full-length Tβ4 human research

What the Research Says

This is the area with the most serious human trial activity, though again centered on full-length Tβ4 rather than the TB-500 fragment. A 2025 randomized controlled trial of recombinant human Tβ4 in 96 patients with acute ST-elevation myocardial infarction did not find a significant reduction in infarct size overall, but did find a significant benefit in the subgroup treated within 8 hours of their procedure.²¹ A separate trial of a different recombinant Tβ4 product is now underway in China for acute MI.²² For the TB-500 fragment, the FDA’s July 2026 review identified no studies administering it to patients.³

What the Real World Says

Cardiac repair is a research and regulatory topic rather than something we found people discussing about their own use — unlike tendon or muscle recovery, this isn't a claim we found circulating in consumer-facing marketing or community discussion to any meaningful degree.

See the ResearchStudies, numbers and limits

The animal foundation

In newborn mice, daily Tβ4 injection extended the brief window during which the heart can regenerate after surgical injury, out to day 7 of life (versus day 1 normally) — with treated hearts showing better ejection fraction and less scarring than untreated controls.¹³
In adult mice given a heart attack, Tβ4 reduced fatal cardiac rupture and improved long-term heart function and blood-vessel density compared with untreated controls.¹⁴

The new TB-500-specific trial

A purported TB-500 cardiovascular trial listing (NCT07487363) describes itself as a fictional example. It is not reliable evidence of a recruiting trial. The FDA’s July 2026 assessment found no studies administering the fragment to patients.³

Other Areas People Talk About

Eye & Corneal Healing

Research: This is where full-length Tβ4 has its strongest human data: a Phase III randomized trial of RGN-259 (a Tβ4 eye-drop formulation) reported significant improvement in corneal healing and comfort for patients with neurotrophic keratopathy, a serious eye condition.²⁰ This result belongs to a specific ophthalmic formulation of the full-length molecule, not to injectable TB-500.

Real World: Not a topic that comes up in TB-500-focused consumer discussion — this evidence exists in a completely different product and context (prescription eye drops) from how TB-500 is marketed and used.

Hair Regrowth

Research: We found no peer-reviewed research testing TB-500 or Tβ4 for hair regrowth specifically.

Real World: This claim circulates in seller marketing (including anecdotal mentions of "grayed hair darkening") but we found no independent, structured reporting on it — it appears to be an unverified marketing claim rather than a documented community pattern.

Real-World Use: What People Are Actually Discussing

The recurring questions from first-person peptide discussions. These are descriptions of online self-experiments, not clinical dosing standards. Reports involving a BPC-157 blend cannot isolate the effects of TB-500.

Why people look into it

Stubborn tendon or ligament problems, lingering joint pain, post-surgery recovery and the popular BPC-157 “Wolverine” combination.

What gets overlooked

People use different products under the TB-500 name. Full-length Tβ4 studies do not validate the short fragment, and user reports range from improvement to no effect or unpleasant reactions.

Anecdotal amounts and frequencyWhy online schedules vary so widely›

What the community says

First-person posts describe daily microgram-scale injections, larger weekly amounts, and combination-vial schedules. For example, one 2026 post described 250 micrograms per day in a BPC-157 combination, while another reported 1 mg twice weekly; a separate poster described a combined vial with a five-days-on/two-days-off schedule. These are individual accounts, not a typical or verified effective range. ²⁶²⁷²⁸

Research says

No validated human dose, route, frequency or dose-response curve exists for the TB-500 fragment. Product identity is particularly important because full-length Tβ4, the seven-amino-acid fragment and blended products are not interchangeable. ⁴²⁵

Timing and injection locationMorning or evening? Near the injury?›

What the community says

Some posts describe injecting near a painful area; others describe abdominal subcutaneous injections and assume a whole-body effect. Discussions about morning versus evening are based largely on convenience or personal reactions, not measured comparisons. ²⁶²⁹

Research says

No human trial has established an effective injection site or time of day for the TB-500 fragment. A local-injection claim should not be treated as proof that the peptide reaches or repairs a specific tendon.

Cycle lengths and what happens afterwardShort injury-focused experiments versus longer use›

What the community says

People discuss several-week experiments, commonly around eight weeks, and ask whether improvement lasts after stopping. A recent discussion described initial knee-pain improvement followed by renewed aches after about six weeks on a BPC-157/TB-500 blend. These posts do not establish a safe cycle or prove the peptide caused either change. ²⁶³⁰

Research says

There is no clinically established cycle length, stopping rule, or long-term safety dataset for the fragment. Recovery from an injury naturally changes over time, especially alongside physiotherapy, rest or other treatments.

Stacking with BPC-157Why the “Wolverine” combination dominates discussions›

What the community says

TB-500 is often discussed alongside BPC-157 for shoulder, knee, Achilles and other soft-tissue complaints. Some posters describe less pain or easier training, while others report little change. Most accounts also involve rehabilitation, altered exercise, or other compounds, making attribution difficult. ²⁷²⁹

Research says

There are no controlled human trials establishing that this exact combination accelerates healing, is synergistic, or is safer than either compound alone. An animal finding is not a validated human stack.

Reported results and side effectsImprovement, no benefit and negative experiences›

What the community says

Posts include reports of reduced back pain or improved workout recovery, alongside no noticeable healing and complaints such as fatigue, hot flashes, anxiety, headache, palpitations or renewed joint aches. Some of the more serious accounts involve BPC-157/TB-500 blends, so the responsible compound cannot be identified. Self-reports cannot establish how frequently any reaction occurs. ^27293031

Research says

The FDA found no human clinical safety studies of the fragment. A lack of formal adverse-event reports is not evidence that an unapproved injectable is safe. Product purity, sterility and even molecular identity are additional uncertainties. ⁴²⁵

What exactly is in the vial?TB-500 fragment, full-length Tβ4 or a blend?›

What sellers and users say

The label “TB-500” is used inconsistently. Discussions may refer to the short 17–23 fragment, full-length thymosin beta-4 or a pre-mixed BPC-157 product as though they were the same substance.

Research says

The FDA’s assessment specifically distinguishes the N-terminal-acetylated seven-amino-acid fragment from the 43-amino-acid parent molecule. A purity percentage alone does not confirm which molecule was tested; identity testing and a product-specific certificate matter. ²⁵

The Takeaway

IN ONE MINUTE

TB-500 attracts interest for tendon, ligament and muscle recovery, especially alongside BPC-157. Laboratory and animal work provides a reason to investigate thymosin beta-4 biology, and full-length Tβ4 has been studied in people. But those results do not establish that the short TB-500 fragment repairs human injuries. Community experiences are mixed, no validated human regimen exists, and product identity and long-term safety remain major unknowns.

What About Safety?

What We Know

Full-length Tβ4 has a real human safety record from its completed Phase 2 trials — those studies reported generally mild, tolerable side-effect profiles at the doses and routes tested (topical gel, eye drops).¹⁷¹⁸ This safety data belongs to the trial-tested formulations, not to injectable TB-500 products sold online.
An equine pharmacokinetic study — a real administration study, though in horses, not people — found TB-500 detectable in blood and urine for several days after a single subcutaneous dose, giving some picture of how the fragment is processed, at least in that species.²

What We Don't Know

No published human pharmacokinetic or dosing data exists for the TB-500 fragment itself — the purported online trial listing is explicitly labelled fictional.³
Long-term safety of repeated TB-500 use in people is entirely unstudied.
Whether TB-500 shares full-length Tβ4's documented human safety profile is an assumption, not a demonstrated fact — the two are different molecules.

Reported / Identified Concerns

FDA reviewers evaluating TB-500 for the compounding pathway flagged a specific concern: that products containing the fragment may carry immunogenicity risk for certain administration routes, related to possible aggregation or peptide-related impurities, and that the agency lacks the human-exposure data needed to assess this.¹⁰
Angiogenesis-promoting peptides carry a theoretical concern about supporting tumor blood-vessel growth in someone with an active, undiagnosed cancer; a 2025 Ukrainian-language academic review of TB-500 and BPC-157 for sports-injury recovery specifically flags this as an unresolved theoretical risk rather than a demonstrated one.²³
TB-500 has a documented history as a doping agent: it was first chemically characterized in 2012 specifically because of suspected use in horse and greyhound racing, and thymosin beta-4 use was central to a case that saw 32 players from an Australian Football League club banned from competition for two years by the Court of Arbitration for Sport.¹²⁴
News coverage following the July 2026 FDA advisory committee vote reported that some panel members had financial ties connected to the peptide industry — relevant context for weighing how the committee's recommendation was reached, separate from the underlying science itself.⁶

Is It Approved or Legal?

Status as of September 2026 — this is an actively developing, investigational drug, and status can change quickly.

United States (FDA)

Investigational — in regulatory limbo

Not approved for any use. In September 2023, the FDA placed TB-500 (with about 18 other peptides) into "Category 2," a designation that effectively barred compounding pharmacies from using it, citing safety concerns including limited human data.⁸ In April 2026, following public pressure from HHS Secretary Robert F. Kennedy Jr., the FDA removed TB-500 and 11 other peptides from Category 2 — but this did not place it on the "may compound" Category 1 list, leaving its compounding status unresolved.⁸⁹ At the July 23, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting, FDA's own scientific reviewers recommended against adding any of the seven peptides under review, including TB-500, citing insufficient safety, efficacy and characterization data. The advisory committee voted contrary to FDA staff's recommendation: TB-500, alongside BPC-157 and KPV, passed 8-6 with one abstention.⁴⁵⁶ This is an advisory recommendation only; the FDA had not issued a final determination as of this build, though the agency has historically tended to follow PCAC's recommendations even where they diverge from its own staff's advice.⁷

Canada

Not authorized

Health Canada has explicitly named TB-500 (as "Thymosin-β4 (TB4 or TB-500)") among unauthorized injectable peptide products in its public advisories on peptides sold online, warning that such products haven't been assessed for safety, efficacy or quality and are illegal to sell in Canada.¹¹

Sport / WADA

Prohibited at all times

TB-500 and thymosin beta-4 are banned under WADA's Prohibited List, Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). This isn't a hypothetical risk: it was central to a 2016 case in which 32 players from an Australian Football League club were suspended for two years by the Court of Arbitration for Sport over a team supplement program.²⁴

TB-500 vs. BPC-157

These two are the most commonly paired recovery peptides, often sold and discussed together. They come from different biological families and are proposed to work through different mechanisms: BPC-157 is a synthetic fragment of a stomach-protective protein, studied mainly for angiogenesis and gut/tissue repair; TB-500 is a synthetic fragment of thymosin beta-4, an actin-regulating protein involved in cell migration. Both are frequently described as complementary rather than redundant — TB-500 marketed as acting more systemically, BPC-157 more locally at an injury site — though this framing comes largely from commercial and clinic sources rather than head-to-head trial data.¹²

The one direct, peer-reviewed comparison we found — a 2026 rat Achilles tendon study testing both peptides alone and combined — is also the source of an important asymmetry: the study's own authors describe BPC-157's tendon-healing evidence base as comparatively well established, while TB-500's is "scarce," with controlled tendon-injury studies "largely absent from the literature" prior to their own.¹² Neither peptide has a completed human efficacy trial for tendon or muscle injury as of this build.

What We Still Don't Know

Does the TB-500 fragment actually work the way full-length Tβ4 does?

This is the central open question. The fragment shares part of the mechanism, but no completed human trial has tested whether it produces the same clinical effects as the longer molecule — the purported online cardiovascular trial listing is explicitly labelled fictional and cannot close that gap.³

Will the FDA finalize the PCAC's recommendation to allow compounding?

Not yet known. FDA staff recommended against including TB-500; the advisory committee voted contrary to that recommendation, in favor of inclusion. Whether the FDA's own final decision follows its staff's assessment or its advisory committee's vote is genuinely unresolved as of this build.⁴⁶

What would a real, validated human dose even look like?

There isn't one. Every dose figure circulating for TB-500 — including the animal-study dose cited on this page — is either an animal dose or an extrapolation from community practice, not a clinically established human dose.

Does gray-market TB-500 actually match the fragment studied in animal research?

This is a real, documented concern rather than a hypothetical one — FDA reviewers specifically flagged aggregation and impurity risks for TB-500 products due to a lack of characterization data, and the same concern is echoed in independent academic literature on black-market peptide quality.¹⁰²³

What does TB-500's cancer-risk profile actually look like?

Unresolved. The theoretical concern (angiogenesis potentially supporting tumor vascularization) is real and specifically named in the literature, but no study has established elevated cancer risk from TB-500 or Tβ4 use in either direction.²³

Quality Matters Too.

Whether the research supports a compound, and whether a specific product actually contains what its label says, are two separate questions — and for TB-500, the FDA's own reviewers have said this second question is unresolved. Their briefing document specifically raises the possibility of aggregation or peptide-related impurities in TB-500 products, and states plainly that the agency lacks the human-exposure data needed to assess the resulting risk.¹⁰

This concern isn't unique to TB-500, but it's stated here with unusual directness by a regulator rather than only by outside critics — worth weighing alongside any product's certificate of analysis, which can speak to identity and purity but not to a product's actual safety or effectiveness in a person.

HOW TO READ A PEPTIDE COA →

Explore Safety & Quality →

Research & References

Every claim on this page traces back to these sources. Open the studies and regulatory documents yourself.

HOW WE RATE THE EVIDENCE →

Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738 — peer-reviewed; the paper that first chemically identified TB-500, in the context of horse and greyhound racing doping investigations.Esposito et al., Drug Testing and Analysis 2012
Ho ENM, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012 — peer-reviewed; a real administration/detection study, in horses.Ho et al., Journal of Chromatography A 2012 (cited via InvivoChem)
NCT07487363 — purported TB-500 cardiovascular study; its summary describes it as a fictional example. Included here to prevent mistaking the listing for evidence of a real recruiting trial.ClinicalTrials.gov, NCT07487363
FDA Evaluation of TB-500-Related Bulk Drug Substances (TB-500 free base and TB-500 acetate) — briefing document prepared for the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting. Primary FDA source.FDA PCAC Briefing Document, TB-500
FDA Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23-24, 2026 — Questions for PCAC Regarding Whether FDA Should Include Certain Bulk Drug Substances on the 503A Bulks List (includes the formal TB-500 vote questions).FDA PCAC meeting questions document
FDA Panel Backs 6 Peptides for Compounding — trade-press coverage confirming the exact vote tallies (BPC-157, KPV and TB-500 passed 8-6 with one abstention; MOTS-c passed 7-5 with two abstentions) and noting FDA staff had recommended against all seven peptides, plus a cited AP report on financial ties among panel members.American Journal of Managed Care, July 31, 2026
Bulk-list bound? PCAC backs majority of peptides in two-day public meeting — law-firm coverage of the July 2026 PCAC meeting, noting the agency has historically tended to follow PCAC recommendations.McDermott Will & Emery
FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings — law-firm summary of the April 2026 Category 2 removal, the HHS Secretary's public comments, and the caveat that removal did not place these peptides on the Category 1 "may compound" list.Orrick
FDA to Remove 12 Popular Peptides from the Category 2 "Do Not Compound" List — corroborating law-firm coverage of the same April 2026 action and its regulatory-limbo effect.Frier Levitt
TB-500 Peptide: Benefits, Safety, Legal Status, and Research — secondary summary citing the FDA's specific immunogenicity/impurity concern and the PCAC's July 23, 2026 recommendation.BSCG (Banned Substances Control Group)
Think twice before injecting peptides bought online: unauthorized products can seriously harm you — Health Canada public advisory explicitly naming Thymosin-β4 (TB4 or TB-500) among unauthorized injectable peptide products.Health Canada
Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. 2026;37(3):822-837 — peer-reviewed rat study, the only direct head-to-head comparison found.Biçer et al., Joint Diseases and Related Surgery 2026
Liu R, Nie Y, Lian H, et al. Extending the time window of mammalian heart regeneration by thymosin beta 4. J Cell Mol Med. 2014 — peer-reviewed, neonatal mouse cardiac regeneration study.Liu et al., Journal of Cellular and Molecular Medicine 2014 (PMC)
Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol. 2014 — peer-reviewed, adult mouse MI study.American Journal of Physiology 2014 (PubMed)
Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse — peer-reviewed, mdx (Duchenne muscular dystrophy model) mouse study.Peer-reviewed mdx mouse study, via PMC
Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999 — peer-reviewed, foundational rat wound-healing study.Journal of Investigative Dermatology 1999 (PubMed)
Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers ("SSVS"), NCT00832091 — completed Phase 2 RCT, RegeneRx Biopharmaceuticals, full-length Tβ4.ClinicalTrials.gov, NCT00832091
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye, NCT01387347 — completed Phase 2 RCT, ReGenTree, full-length Tβ4; co-primary endpoints not significant, secondary endpoint improved.ClinicalTrials.gov, NCT01387347
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds, NCT00598871 — terminated Phase 2 RCT (slow recruitment), ReGenTree, full-length Tβ4.ClinicalTrials.gov, NCT00598871
Sosne G, et al. Phase III RCT of RGN-259 (thymosin beta-4 ophthalmic solution) for neurotrophic keratopathy — peer-reviewed, positive result, cited via secondary summary.Cited via Superpower Health thymosin beta-4 guide
Zhang et al. Human RCT of recombinant thymosin beta-4 in 96 patients with acute ST-elevation myocardial infarction, Cardiovascular Research, 2025 — peer-reviewed; no significant overall reduction in infarct size, positive subgroup signal within 8 hours of PCI, cited via secondary summary.Cited via Superpower Health thymosin beta-4 guide
Recombinant Human Thymosin Beta 4 for Injection (NL005) for Acute Myocardial Infarction, NCT07586865 — registered trial, recombinant full-length Tβ4, not yet reported.ClinicalTrials.gov, NCT07586865
Чорномидз А., Кланца М. "Сіра зона" фармакології: огляд пептидних біорегуляторів для відновлення після спортивних травм (BPC-157, TB-500) ["The grey zone" of pharmacology: a review of peptide bioregulators for post-sports-injury recovery (BPC-157, TB-500)]. Physical Culture and Sport: Scientific Perspective. 2025;4:14-23. Ternopil National Medical University. Ukrainian-language peer-reviewed review article — read in the original language; no official English translation exists, machine-assisted reading used to confirm content matches the English abstract provided by the journal.Chornomydz & Klantsa, Physical Culture and Sport 2025 (Ukrainian)
Thymosin beta-4 use in the 2016 Court of Arbitration for Sport case resulting in two-year bans for 32 Essendon Football Club (AFL) players — cited via secondary sports-medicine summary.Cited via Sports Injury Physio
FDA, July 2026 Pharmacy Compounding Advisory Committee: TB-500 assessment. No published studies administering the fragment to patients; full-length thymosin beta-4 is a different molecule.Open original source
Reddit r/Biohacking, July 2026: first-person BPC-157/TB-500 knee-injury discussion, including self-reported daily use and an eight-week plan.Open original source
Reddit r/bpc_157, December 2025: 30-day BPC-157/TB-500 experience, reported recovery and limitations.Open original source
Reddit r/bpc_157, October 2025: self-reported combined-vial schedule after foot surgery.Open original source
Reddit r/Peptides, December 2023: mixed first-person TB-500 side-effect and recovery discussion.Open original source
Reddit r/bpc_157, September 2026: recurring joint aches after an initial improvement on a BPC-157/TB-500 blend.Open original source
Reddit r/Peptidesource, June 2024: adverse symptoms reported after a seven-week BPC-157/TB-500 combination.Open original source

Where to Next?

Safety & QualityHow to Read a Peptide COA ExploreSee All Peptides A–Z LearnHow We Grade the Evidence

Still Confused?

Peptide research can get complicated quickly. If you'd rather talk it through with someone who can help you understand the terminology, research and questions worth asking:

General education only — not medical advice.

GET HELP UNDERSTANDING YOUR OPTIONS